Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers

NCT04018170
terminatedphase_2

LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer

NCT02538471
completedphase_1

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

NCT02201849
completed

Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

NCT01270711

Clinical Trials (4)

Showing 4 of 4 trials
NCT04018170Phase 1

Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers

Completed
NCT02538471Phase 2

LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer

Terminated
NCT02201849Phase 1

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

Completed
NCT01270711

Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4